RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:213792

Adenosarcoma of the cervix uteri

medium confidenceDisorder

Also known as: Cervical adenosarcoma

Publications

230

71th percentile

Trials

1

Interventional, condition-specific

Researchers

1,086

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare subtype of malignant mixed epithelial and mesenchymal tumor composed of benign or mildly atypical glandular elements and a surrounding low-grade malignant stroma, often containing heterologous elements, such as areas of sex-cord-like or smooth muscle differentiation. It usually presents with vaginal bleeding or discharge, lower abdominal pain and/or a cervical mass or polyp. The tumor may arise from pre-existing endometriosis and patients may have a history of recurrent cervical polyps.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

adenosarcoma of the cervix uteri · adenosarcoma of uterine cervix · cervical Mullerian adenosarcoma · cervical Müllerian adenosarcoma · cervical adenosarcoma · uterine cervix adenosarcoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    230 matched papers (130 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

230

230 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

230 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

130 in the last 10 years · medium confidence · 71th percentile (publications denominator)

Phrase hits: 230 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,086

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wei F6 papers · 2026

    Department of Orthopaedics, Peking University Third Hospital; Engineering Research Center of Bone and Joint Precision Medicine; Beijing Key Laboratory of Spinal Disease Research, Beijing 100191, China.

    Papers in Europe PMC
  2. 02
    Zhou H6 papers · 2025

    Department of Orthopaedics, Peking University Third Hospital; Engineering Research Center of Bone and Joint Precision Medicine; Beijing Key Laboratory of Spinal Disease Research, Beijing 100191, China.

    Papers in Europe PMC
  3. 03
    Liu X5 papers · 2025

    Orthopedic Department, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC
  4. 04
    Li Y4 papers · 2025

    Department of Spine, Second Hospital of Tangshan, Tangshan, Hebei, China 063000.

    Papers in Europe PMC
  5. 05
    Liu Z4 papers · 2025

    Orthopedic Department, Peking University Third Hospital, Beijing, China. zjliu@bjmu.edu.cn.

    Papers in Europe PMC
  6. 06
    Chen L3 papers · 2026

    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.

    Papers in Europe PMC
  7. 07
    Dang L3 papers · 2025

    Department of Orthopaedics, Peking University Third Hospital; Engineering Research Center of Bone and Joint Precision Medicine; Beijing Key Laboratory of Spinal Disease Research, Beijing 100191, China.

    Papers in Europe PMC
  8. 08
    Gokaslan ZL3 papers · 2026

    8Department of Neurosurgery, Brown University, Warren Alpert School of Medicine, Providence, Rhode Island.

    Papers in Europe PMC
  9. 09
    Jiang L3 papers · 2018

    Department of Orthopedic Surgery, Peking University Third Hospital, Beijing, 100191, China.

    Papers in Europe PMC
  10. 10
    Yang J3 papers · 2019

    Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, 4365 Kangxin Road, Shanghai, 201315, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 2 trials are registered for adenosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).

medium confidence · 76.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: adenosarcoma

2

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Adenosarcoma of the cervix uteri" OR "Adenosarcoma of cervix uteri" OR "Cervical adenosarcoma" OR "adenosarcoma of uterine cervix" OR "adenosarcoma of the uterine cervix" OR "cervical Mullerian adenosarcoma" OR "cervical Müllerian adenosarcoma" OR "uterine cervix adenosarcoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Adenosarcoma of the cervix uteri" OR "Adenosarcoma of cervix uteri" OR "Cervical adenosarcoma" OR "adenosarcoma of uterine cervix" OR "adenosarcoma of the uterine cervix" OR "cervical Mullerian adenosarcoma" OR "cervical Müllerian adenosarcoma" OR "uterine cervix adenosarcoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"adenosarcoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (230) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T09:39:15.277Z